Prospective Study of Intensity-Modulated Proton Therapy (IMPT) for Small Cell Lung Cancer
To assess the safety and efficacy of intensity-modulated proton therapy (IMPT) for small cell lung cancer (SCLC)
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Sep 17, 2026 · Source: ClinicalTrials.gov
The study is currently accepting participants.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Emory University
- Interventions being studied
- Radiation: Proton-beam Therapy for Small Cell Lung Cancer
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Pathologically confirmed small cell lung cancer, limited or extensive stage.
- Patients who are offered thoracic radiotherapy with intensity-modulated proton therapy (IMPT) techniques delivering 30-66 Gy in 15-33 fractions at 2 Gy per fraction, at the recommendation of the treating radiation oncologist.
- Age 18 or greater
- Prior radiation therapy which would provide significant dose overlap with the planned target volume(s)
- Pregnancy
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Winship Cancer InstituteAtlanta, Georgia
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 17, 2026. Always confirm current availability with the study team.